Publikationen

2023

NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats.

Lipinski B, Arras P, Pekar L, Klewinghaus D, Boje AS, Krah S, Zimmermann J, Klausz K, Peipp M, Siegmund V, Evers A, Zielonka S.Protein Sci. 2023 Mar;32(3):e4593. doi: 10.1002/pro.4593.PMID: 36775946 Free PMC article.

2022

Editorial: Effector functions of therapeutic antibodies.

Boross P, Peipp M, Nimmerjahn F.Front Immunol. 2023 Jan 12;13:1126966. doi: 10.3389/fimmu.2022.1126966. eCollection 2022.PMID: 36713416 Free PMC article. No abstract available.

 

Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia.

Bäumer N, Scheller A, Wittmann L, Faust A, Apel M, Nimmagadda SC, Geyer C, Grunert K, Kellmann N, Peipp M, Kailayangiri S, Gutierrez Suburu ME, Strassert CA, Schenk M, Greune L, Rüter C, Dersch P, Hartmann W, Rossig C, Neri D, Müller-Tidow C, Schwöppe C, Schliemann C, Khandanpour C, Lenz G, Berdel WE, Bäumer S.J Hematol Oncol. 2022 Dec 1;15(1):171. doi: 10.1186/s13045-022-01390-5.PMID: 36457063 Free PMC article.

 

The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.

Geisen UM, Rose R, Neumann F, Ciripoi M, Vullriede L, Reid HM, Berner DK, Bertoglio F, Hoff P, Hust M, Longardt AC, Lorentz T, Martini GR, Saggau C, Schirmer JH, Schubert M, Sümbül M, Tran F, Voß M, Zeuner R, Morrison PJ, Bacher P, Fickenscher H, Gerdes S, Peipp M, Schreiber S, Krumbholz A, Hoyer BF.J Med Virol. 2022 Dec;94(12):5780-5789. doi: 10.1002/jmv.28063. Epub 2022 Aug 19.PMID: 35945627 Free PMC article.

 

Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.

Klausz K, Pekar L, Boje AS, Gehlert CL, Krohn S, Gupta T, Xiao Y, Krah S, Zaynagetdinov R, Lipinski B, Toleikis L, Poetzsch S, Rabinovich B, Peipp M, Zielonka S.J Immunol. 2022 Nov 1;209(9):1724-1735. doi: 10.4049/jimmunol.2100970. Epub 2022 Sep 14.PMID: 36104113

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.

Zeller T, Lutz S, Münnich IA, Windisch R, Hilger P, Herold T, Tahiri N, Banck JC, Weigert O, Moosmann A, von Bergwelt-Baildon M, Flamann C, Bruns H, Wichmann C, Baumann N, Valerius T, Schewe DM, Peipp M, Rösner T, Humpe A, Kellner C.Front Immunol. 2022 Oct 27;13:929339. doi: 10.3389/fimmu.2022.929339. eCollection 2022.PMID: 36389667 Free PMC article.

 

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.

Gehlert CL, Rahmati P, Boje AS, Winterberg D, Krohn S, Theocharis T, Cappuzzello E, Lux A, Nimmerjahn F, Ludwig RJ, Lustig M, Rösner T, Valerius T, Schewe DM, Kellner C, Klausz K, Peipp M.Front Immunol. 2022 Aug 31;13:957874. doi: 10.3389/fimmu.2022.957874. eCollection 2022.PMID: 36119088 Free PMC article.

 

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.

Vogiatzi F, Heymann J, Müller K, Winterberg D, Drakul A, Rösner T, Lenk L, Heib M, Gehlert CL, Cario G, Schrappe M, Claviez A, Bornhauser B, Bourquin JP, Bomken S, Adam D, Frielitz FS, Maecker-Kolhoff B, Stanulla M, Valerius T, Peipp M, Kellner C, Schewe DM.Blood Adv. 2022 Aug 23;6(16):4847-4858. doi: 10.1182/bloodadvances.2022007364.PMID: 35820018 Free PMC article.

 

The relevance of complement in pemphigoid diseases: A critical appraisal.

Papara C, Karsten CM, Ujiie H, Schmidt E, Schmidt-Jiménez LF, Baican A, Freire PC, Izumi K, Bieber K, Peipp M, Verschoor A, Ludwig RJ, Köhl J, Zillikens D, Hammers CM.Front Immunol. 2022 Aug 16;13:973702. doi: 10.3389/fimmu.2022.973702. eCollection 2022.PMID: 36059476 Free PMC article. Review.

 

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.

Baumann N, Arndt C, Petersen J, Lustig M, Rösner T, Klausz K, Kellner C, Bultmann M, Bastian L, Vogiatzi F, Leusen JHW, Burger R, Schewe DM, Peipp M, Valerius T.Front Immunol. 2022 Aug 16;13:949140. doi: 10.3389/fimmu.2022.949140. eCollection 2022.PMID: 36052078 Free PMC article.

 

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia.

Lenk L, Winterberg D, Vogiatzi F, Laqua A, Spory L, Mayar A, Dietterle A, Münch G, Vokuhl C, Richter J, Polson AG, Schüler T, Kahlert UD, Peipp M, Valerius T, Schrappe M, Cario G, Jumaa H, Hobeika E, Brüggemann M, Alsadeq A, Schewe DM.Hemasphere. 2022 Jul 15;6(8):e754. doi: 10.1097/HS9.0000000000000754. eCollection 2022 Aug.PMID: 35935606 Free PMC article. No abstract available.

 

Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.

Peipp M, Klausz K, Boje AS, Zeller T, Zielonka S, Kellner C.Clin Exp Immunol. 2022 Jul 22;209(1):22-32. doi: 10.1093/cei/uxac028.PMID: 35325068 Free PMC article. Review.

 

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.

Müller K, Vogiatzi F, Winterberg D, Rösner T, Lenk L, Bastian L, Gehlert CL, Autenrieb MP, Brüggemann M, Cario G, Schrappe M, Kulozik AE, Eckert C, Bergmann AK, Bornhauser B, Bourquin JP, Valerius T, Peipp M, Kellner C, Schewe DM.Blood. 2022 Jul 7;140(1):45-57. doi: 10.1182/blood.2021014485.PMID: 35452517

 

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display.

Krohn S, Boje AS, Gehlert CL, Lutz S, Darzentas N, Knecht H, Herrmann D, Brüggemann M, Scheidig AJ, Weisel K, Gramatzki M, Peipp M, Klausz K.Front Immunol. 2022 Jun 17;13:908093. doi: 10.3389/fimmu.2022.908093. eCollection 2022.PMID: 35784366 Free PMC article.

 

Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen.

Kellner C, Lutz S, Oberg HH, Wesch D, Otte A, Diemer KJ, Wilcken H, Bauerschlag D, Glüer CC, Wichmann C, Kabelitz D, Leusen JHW, Klausz K, Humpe A, Gramatzki M, Peipp M.Biol Chem. 2021 Oct 29;403(5-6):545-556. doi: 10.1515/hsz-2021-0229. Print 2022 Apr 26.PMID: 34717050 Free article.

 

Targeted siRNA nanocarrier: a platform technology for cancer treatment.

Bäumer N, Tiemann J, Scheller A, Meyer T, Wittmann L, Suburu MEG, Greune L, Peipp M, Kellmann N, Gumnior A, Brand C, Hartmann W, Rossig C, Müller-Tidow C, Neri D, Strassert CA, Rüter C, Dersch P, Lenz G, Koeffler HP, Berdel WE, Bäumer S.Oncogene. 2022 Apr;41(15):2210-2224. doi: 10.1038/s41388-022-02241-w. Epub 2022 Feb 26.PMID: 35220407 Free PMC article.

 

Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.

Sahin M, Remy MM, Fallet B, Sommerstein R, Florova M, Langner A, Klausz K, Straub T, Kreutzfeldt M, Wagner I, Schmidt CT, Malinge P, Magistrelli G, Izui S, Pircher H, Verbeek JS, Merkler D, Peipp M, Pinschewer DD.Cell Rep. 2022 Feb 1;38(5):110303. doi: 10.1016/j.celrep.2022.110303.PMID: 35108544 Free PMC article.

2021

The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity In Vitro and In Vivo.

Klausz K, Kellner C, Gehlert CL, Krohn S, Wilcken H, Floerkemeier I, Günther A, Bauerschlag DO, Clement B, Gramatzki M, Peipp M.Mol Cancer Ther. 2022 Jan;21(1):70-78. doi: 10.1158/1535-7163.MCT-21-0119. Epub 2021 Nov 1.PMID: 34725192

 

CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.

Stoll A, Bruns H, Fuchs M, Völkl S, Nimmerjahn F, Kunz M, Peipp M, Mackensen A, Mougiakakos D.Leukemia. 2021 Dec;35(12):3482-3496. doi: 10.1038/s41375-021-01287-1. Epub 2021 May 21.PMID: 34021248 Free PMC article.

 

The selection of variable regions affects effector mechanisms of IgA antibodies against CD20.

Evers M, Rösner T, Dünkel A, Jansen JHM, Baumann N, Ten Broeke T, Nederend M, Eichholz K, Klausz K, Reiding K, Schewe DM, Kellner C, Peipp M, Leusen JHW, Valerius T.Blood Adv. 2021 Oct 12;5(19):3807-3820. doi: 10.1182/bloodadvances.2021004598.PMID: 34525171 Free PMC

 

Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks in vivo tumor growth.

Burger R, Otte A, Brdon J, Peipp M, Gramatzki M.Haematologica. 2021 Sep 1;106(9):2507-2510. doi: 10.3324/haematol.2020.276865.PMID: 33882638 Free PMC article. No abstract available.

 

 

Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.

Baumann N, Rösner T, Jansen JHM, Chan C, Marie Eichholz K, Klausz K, Winterberg D, Müller K, Humpe A, Burger R, Peipp M, Schewe DM, Kellner C, Leusen JHW, Valerius T.Cancer Sci. 2021 Aug;112(8):3029-3040. doi: 10.1111/cas.14999. Epub 2021 Jun 18.PMID: 34058788 Free PMC article.

 

Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy.

Klausz K, Cieker M, Kellner C, Rösner T, Otte A, Krohn S, Lux A, Nimmerjahn F, Valerius T, Gramatzki M, Peipp M.Haematologica. 2021 Jul 1;106(7):1857-1866. doi: 10.3324/haematol.2020.251371.PMID: 32499243 Free PMC article.

 

Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma.

Lejeune M, Duray E, Peipp M, Clémenceau B, Baron F, Beguin Y, Caers J.Cancers (Basel). 2021 Jun 20;13(12):3072. doi: 10.3390/cancers13123072.PMID: 34203012 Free PMC article.

 

Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo.

Winterberg D, Lenk L, Oßwald M, Vogiatzi F, Gehlert CL, Frielitz FS, Klausz K, Rösner T, Valerius T, Trauzold A, Peipp M, Kellner C, Schewe DM.J Clin Med. 2021 Jun 15;10(12):2634. doi: 10.3390/jcm10122634.PMID: 34203833 Free PMC article.

 

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer.

Lüftner D, Peipp M.Geburtshilfe Frauenheilkd. 2021 Jun;81(6):666-678. doi: 10.1055/a-1471-4063. Epub 2021 Jun 21.PMID: 34168380 Free PMC article.

 

Suppression of IgE-mediated anaphylaxis and food allergy with monovalent anti-FcεRIα mAbs.

Khodoun MV, Morris SC, Shao WH, Potter C, Angerman E, Kiselev A, Yarawsky AE, Herr AB, Klausz K, Otte A, Peipp M, Finkelman FD.J Allergy Clin Immunol. 2021 May;147(5):1838-1854.e4. doi: 10.1016/j.jaci.2020.10.045. Epub 2020 Dec 14.PMID: 33326804 Free PMC article.

 

Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.

Bondza S, Marosan A, Kara S, Lösing J, Peipp M, Nimmerjahn F, Buijs J, Lux A.Front Immunol. 2021 Jan 11;11:609941. doi: 10.3389/fimmu.2020.609941. eCollection 2020.PMID: 33505398 Free PMC article.

 

Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.

Pekar L, Klausz K, Busch M, Valldorf B, Kolmar H, Wesch D, Oberg HH, Krohn S, Boje AS, Gehlert CL, Toleikis L, Krah S, Gupta T, Rabinovich B, Zielonka S, Peipp M.J Immunol. 2021 Jan 1;206(1):225-236. doi: 10.4049/jimmunol.2001004. Epub 2020 Dec 2.PMID: 33268483 Free PMC article.

2020

Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies.

Macarrón Palacios A, Grzeschik J, Deweid L, Krah S, Zielonka S, Rösner T, Peipp M, Valerius T, Kolmar H.Front Immunol. 2020 Nov 26;11:560244. doi: 10.3389/fimmu.2020.560244. eCollection 2020.PMID: 33324393 Free PMC article.

 

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering.

Roßkopf S, Eichholz KM, Winterberg D, Diemer KJ, Lutz S, Münnich IA, Klausz K, Rösner T, Valerius T, Schewe DM, Humpe A, Gramatzki M, Peipp M, Kellner C.Antibodies (Basel). 2020 Nov 17;9(4):63. doi: 10.3390/antib9040063.PMID: 33212776 Free PMC article.

 

Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity.

Gonnermann D, Oberg HH, Lettau M, Peipp M, Bauerschlag D, Sebens S, Kabelitz D, Wesch D.Front Immunol. 2020 Jun 30;11:1328. doi: 10.3389/fimmu.2020.01328. eCollection 2020.PMID: 32695112 Free PMC article.

 

Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.

Oberg HH, Janitschke L, Sulaj V, Weimer J, Gonnermann D, Hedemann N, Arnold N, Kabelitz D, Peipp M, Bauerschlag D, Wesch D.J Leukoc Biol. 2020 Jun;107(6):1081-1095. doi: 10.1002/JLB.5MA1119-265R. Epub 2019 Dec 13.PMID: 31833593 Free PMC article.

 

Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivo.

Schaffert A, Hanić M, Novokmet M, Zaytseva O, Krištić J, Lux A, Nitschke L, Peipp M, Pezer M, Hennig R, Rapp E, Lauc G, Nimmerjahn F.Front Immunol. 2020 Jan 9;10:3024. doi: 10.3389/fimmu.2019.03024. eCollection 2019.PMID: 31998308 Free PMC article.

2019

TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells.

Tawfik D, Groth C, Gundlach JP, Peipp M, Kabelitz D, Becker T, Oberg HH, Trauzold A, Wesch D.Front Immunol. 2019 Aug 28;10:2044. doi: 10.3389/fimmu.2019.02044. eCollection 2019.PMID: 31555275 Free PMC article.

 

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.

Vogiatzi F, Winterberg D, Lenk L, Buchmann S, Cario G, Schrappe M, Peipp M, Richter-Pechanska P, Kulozik AE, Lentes J, Bergmann AK, Valerius T, Frielitz FS, Kellner C, Schewe DM.Blood. 2019 Aug 22;134(8):713-716. doi: 10.1182/blood.2019000904. Epub 2019 Jul 16.PMID: 31311816 Free article. No abstract available.

 

Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.

Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M.Mol Cancer Ther. 2019 Apr;18(4):823-833. doi: 10.1158/1535-7163.MCT-18-0849. Epub 2019 Mar 1.PMID: 30824613

 

FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.

Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen PJJH, Geissler J, Lissenberg-Thunnissen S, Valerius T, Peipp M, Franke K, van Bruggen R, Kuijpers TW, van Egmond M, Vidarsson G, Matlung HL, van den Berg TK.Front Immunol. 2019 Jan 30;9:3124. doi: 10.3389/fimmu.2018.03124. eCollection 2018.PMID: 30761158 Free PMC article.

2018

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, Rösner T, Dechant M, Derer S, Klausz K, Kellner C, Schwanbeck R, French RR, Tipton TRW, Cragg MS, Schewe DM, Peipp M, Leusen JHW, Valerius T.Br J Haematol. 2018 May;181(3):413-417. doi: 10.1111/bjh.14624. Epub 2017 Apr 27.PMID: 28449349 Free article. No abstract available.

 

Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.

Oberg HH, Kellner C, Gonnermann D, Sebens S, Bauerschlag D, Gramatzki M, Kabelitz D, Peipp M, Wesch D.Front Immunol. 2018 Apr 19;9:814. doi: 10.3389/fimmu.2018.00814. eCollection 2018.PMID: 29725336 Free PMC article.

 

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia.

Kellner C, Peipp M, Gramatzki M, Schrappe M, Schewe DM.Oncoimmunology. 2018 Apr 9;7(8):e1448331. doi: 10.1080/2162402X.2018.1448331. eCollection 2018.PMID: 30221037 Free PMC article.

 

Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.

Kellner C, Derer S, Klausz K, Rosskopf S, Wirt T, Rösner T, Otte A, Cappuzzello E, Peipp M.Methods Mol Biol. 2018;1827:381-397. doi: 10.1007/978-1-4939-8648-4_20.PMID: 30196508

2017

CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.

Peipp M, Wesch D, Oberg HH, Lutz S, Muskulus A, van de Winkel JGJ, Parren PWHI, Burger R, Humpe A, Kabelitz D, Gramatzki M, Kellner C.Scand J Immunol. 2017 Oct;86(4):196-206. doi: 10.1111/sji.12581.PMID: 28708284 Free article.

 

A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.

Klausz K, Cieker M, Kellner C, Oberg HH, Kabelitz D, Valerius T, Burger R, Gramatzki M, Peipp M.Oncotarget. 2017 Sep 5;8(44):77552-77566. doi: 10.18632/oncotarget.20641. eCollection 2017 Sep 29.PMID: 29100408 Free PMC article.

 

 

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.

Schewe DM, Alsadeq A, Sattler C, Lenk L, Vogiatzi F, Cario G, Vieth S, Valerius T, Rosskopf S, Meyersieck F, Alten J, Schrappe M, Gramatzki M, Peipp M, Kellner C.Blood. 2017 Sep 28;130(13):1543-1552. doi: 10.1182/blood-2017-01-764316. Epub 2017 Jul 11.PMID: 28698205 Free article.

 

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.

Kellner C, Otte A, Cappuzzello E, Klausz K, Peipp M.Transfus Med Hemother. 2017 Sep;44(5):327-336. doi: 10.1159/000479980. Epub 2017 Sep 8.PMID: 29070978 Free PMC article. Review.

 

An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.

Wirt T, Rosskopf S, Rösner T, Eichholz KM, Kahrs A, Lutz S, Kretschmer A, Valerius T, Klausz K, Otte A, Gramatzki M, Peipp M, Kellner C.Transfus Med Hemother. 2017 Sep;44(5):292-300. doi: 10.1159/000479978. Epub 2017 Sep 11.PMID: 29070974 Free PMC article.

 

Antibody Engineering - Tailor-Made Next Generation Antibodies by Molecular Design.

Humpe A, Peipp M.Transfus Med Hemother. 2017 Sep;44(5):290-291. doi: 10.1159/000479617. Epub 2017 Sep 13.PMID: 29070973 Free PMC article. No abstract available.

 

Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.

Burger R, Günther A, Klausz K, Staudinger M, Peipp M, Penas EM, Rose-John S, Wijdenes J, Gramatzki M.Haematologica. 2017 Feb;102(2):381-390. doi: 10.3324/haematol.2016.145060. Epub 2016 Sep 22.PMID: 27658435 Free PMC article.

2016

Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.

Oberg HH, Grage-Griebenow E, Adam-Klages S, Jerg E, Peipp M, Kellner C, Petrick D, Gonnermann D, Freitag-Wolf S, Röcken C, Sebens T, Vogel I, Becker T, Ebsen M, Kabelitz D, Wesch D, Sebens S.Pancreatology. 2016 Nov-Dec;16(6):1069-1079. doi: 10.1016/j.pan.2016.07.008. Epub 2016 Jul 11.PMID: 27424476

2015

An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.

Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen JH, Valerius T.Cancer Res. 2016 Jan 15;76(2):403-17. doi: 10.1158/0008-5472.CAN-15-1232. Epub 2015 Dec 3.PMID: 26634925

 

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.Oncoimmunology. 2015 Jun 5;5(1):e1058459. doi: 10.1080/2162402X.2015.1058459. eCollection 2016.PMID: 26942070 Free PMC article.

 

A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.

Derer S, Cossham M, Rösner T, Kellner C, Beurskens FJ, Schwanbeck R, Lohse S, Sina C, Peipp M, Valerius T.J Immunol. 2015 Nov 15;195(10):5077-87. doi: 10.4049/jimmunol.1501458. Epub 2015 Oct 16.PMID: 26475927

 

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.

Peipp M, Derer S, Lohse S, Staudinger M, Klausz K, Valerius T, Gramatzki M, Kellner C.Oncotarget. 2015 Oct 13;6(31):32075-88. doi: 10.18632/oncotarget.5135.PMID: 26392331 Free PMC article.

 

Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic Cancer Cells.

Geisen U, Zenthoefer M, Peipp M, Kerber J, Plenge J, Managò A, Fuhrmann M, Geyer R, Hennig S, Adam D, Piker L, Rimbach G, Kalthoff H.Mar Drugs. 2015 Jul 20;13(7):4470-91. doi: 10.3390/md13074470.PMID: 26204945 Free PMC article.

 

γδ T cell activation by bispecific antibodies.

Oberg HH, Kellner C, Gonnermann D, Peipp M, Peters C, Sebens S, Kabelitz D, Wesch D.Cell Immunol. 2015 Jul;296(1):41-9. doi: 10.1016/j.cellimm.2015.04.009. Epub 2015 May 1.PMID: 25979810

Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.

Gonnermann D, Oberg HH, Kellner C, Peipp M, Sebens S, Kabelitz D, Wesch D.Oncoimmunology. 2015 Jan 7;4(3):e988460. doi: 10.4161/2162402X.2014.988460. eCollection 2015 Mar.PMID: 25949900 Free PMC article.

 

The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.

Klausz K, Kellner C, Derer S, Valerius T, Staudinger M, Burger R, Gramatzki M, Peipp M.J Immunol Methods. 2015 Mar;418:75-83. doi: 10.1016/j.jim.2015.02.002. Epub 2015 Feb 18.PMID: 25701195

2014

Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy.

Oberg HH, Kellner C, Peipp M, Sebens S, Adam-Klages S, Gramatzki M, Kabelitz D, Wesch D.Front Immunol. 2014 Dec 17;5:643. doi: 10.3389/fimmu.2014.00643. eCollection 2014.PMID: 25566256 Free PMC article. Review.

 

Fc-optimized antibodies quickly pull the trigger.

Kellner C, Peipp M.Blood. 2014 Nov 20;124(22):3180-1. doi: 10.1182/blood-2014-10-602219.PMID: 25414435 Free article.

 

Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.

Rösner T, Lohse S, Peipp M, Valerius T, Derer S.J Immunol. 2014 Aug 1;193(3):1485-95. doi: 10.4049/jimmunol.1400329. Epub 2014 Jun 27.PMID: 24973443 Clinical Trial.

 

The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.

Staudinger M, Glorius P, Burger R, Kellner C, Klausz K, Günther A, Repp R, Klapper W, Gramatzki M, Peipp M.Blood Cancer J. 2014 Jun 13;4(6):e219. doi: 10.1038/bcj.2014.38.PMID: 24927408 Free PMC article.

 

 

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

de Goeij BE, Peipp M, de Haij S, van den Brink EN, Kellner C, Riedl T, de Jong R, Vink T, Strumane K, Bleeker WK, Parren PW.MAbs. 2014 Mar-Apr;6(2):392-402. doi: 10.4161/mabs.27705. Epub 2014 Jan 3.PMID: 24492309 Free PMC article.

 

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.

Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, Desjarlais JR, Humpe A, Valerius T, Peipp M.MAbs. 2014 Mar-Apr;6(2):409-21. doi: 10.4161/mabs.27457. Epub 2013 Dec 11.PMID: 24492248 Free PMC article.

 

Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.

Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, Adam-Klages S, Röcken C, Becker T, Vogel I, Weisner D, Freitag-Wolf S, Gramatzki M, Kabelitz D, Wesch D.Cancer Res. 2014 Mar 1;74(5):1349-60. doi: 10.1158/0008-5472.CAN-13-0675. Epub 2014 Jan 21.PMID: 24448235

 

Complement in antibody-based tumor therapy.

Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T.Crit Rev Immunol. 2014;34(3):199-214. doi: 10.1615/critrevimmunol.2014009761.PMID: 24941073 Review.

 

Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization.

Derer S, Kellner C, Rösner T, Klausz K, Glorius P, Valerius T, Peipp M.Methods Mol Biol. 2014;1131:525-40. doi: 10.1007/978-1-62703-992-5_33.PMID: 24515488

 

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions.

Kellner C, Derer S, Valerius T, Peipp M.Methods. 2014 Jan 1;65(1):105-13. doi: 10.1016/j.ymeth.2013.06.036. Epub 2013 Jul 9.PMID: 23851282

2013

Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.

Brunke C, Lohse S, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, Royle L, Liew LP, Leusen JH, Valerius T.MAbs. 2013 Nov-Dec;5(6):936-45. doi: 10.4161/mabs.26396.PMID: 24492345 Free PMC article.

 

IgA EGFR antibodies mediate tumour killing in vivo.

Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH.EMBO Mol Med. 2013 Aug;5(8):1213-26. doi: 10.1002/emmm.201201929.PMID: 23918228 Free PMC article.

 

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.

Kellner C, Zhukovsky EA, Pötzke A, Brüggemann M, Schrauder A, Schrappe M, Kneba M, Repp R, Humpe A, Gramatzki M, Peipp M.Leukemia. 2013 Jul;27(7):1595-8. doi: 10.1038/leu.2012.373. Epub 2013 Jan 1.PMID: 23277329 No abstract available.

 

Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype.

Kellner C, Gramatzki M, Peipp M.Oncoimmunology. 2013 Jun 1;2(6):e24481. doi: 10.4161/onci.24481. Epub 2013 May 9.PMID: 23894708 Free PMC article.

 

An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.

Rösner T, Derer S, Kellner C, Dechant M, Lohse S, Vidarsson G, Peipp M, Valerius T.Br J Haematol. 2013 Apr;161(2):282-6. doi: 10.1111/bjh.12209. Epub 2013 Jan 7.PMID: 23294176 Free article. No abstract available.

 

ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.

Trad A, Hansen HP, Shomali M, Peipp M, Klausz K, Hedemann N, Yamamoto K, Mauermann A, Desel C, Lorenzen I, Lemke H, Rose-John S, Grötzinger J.Cancer Immunol Immunother. 2013 Mar;62(3):411-21. doi: 10.1007/s00262-012-1346-x. Epub 2012 Sep 1.PMID: 22940887

 

 

Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis.

Koch T, Derer S, Staudinger M, Rossen K, Glorius P, Peipp M, Kellner C, Kunzendorf U, Valerius T, Dechant M.Am J Nephrol. 2013;38(5):379-87. doi: 10.1159/000355972. Epub 2013 Oct 23.PMID: 24157422

 

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.

Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, Beurskens FJ, Parren PW, Winkel JG, Valerius T, Humpe A, Repp R, Gramatzki M, Nimmerjahn F, Peipp M.Leukemia. 2013 Jan;27(1):190-201. doi: 10.1038/leu.2012.150. Epub 2012 Jun 4.PMID: 22660187

2012

Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies.

Derer S, Bauer P, Lohse S, Scheel AH, Berger S, Kellner C, Peipp M, Valerius T.J Immunol. 2012 Dec 1;189(11):5230-9. doi: 10.4049/jimmunol.1202037. Epub 2012 Oct 24.PMID: 23100515

 

Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.

Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M, Peipp M.J Immunol. 2012 Nov 15;189(10):5037-46. doi: 10.4049/jimmunol.1201321. Epub 2012 Oct 12.PMID: 23066150

 

Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.

Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JG, Leusen JH, Valerius T.J Biol Chem. 2012 Jul 20;287(30):25139-50. doi: 10.1074/jbc.M112.353060. Epub 2012 Jun 7.PMID: 22679018 Free PMC article.

 

Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.

Lammerts van Bueren JJ, Bleeker WK, Brännström A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW.Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5548. doi: 10.1073/pnas.1203736109. Epub 2012 Mar 19.PMID: 22431606 Free PMC article. No abstract available.

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.

Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, Valerius T, Repp R, Humpe A, Gramatzki M, Peipp M.Leukemia. 2012 Apr;26(4):830-4. doi: 10.1038/leu.2011.288. Epub 2011 Oct 18.PMID: 22005785 No abstract available.

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, Scheel AH, Lammerts van Bueren JJ, van de Winkel JG, Parren PW, Peipp M, Valerius T.Neoplasia. 2012 Mar;14(3):190-205. doi: 10.1593/neo.111636.PMID: 22496619 Free PMC article.

 

Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.

Derer S, Kellner C, Berger S, Valerius T, Peipp M.Methods Mol Biol. 2012;907:519-36. doi: 10.1007/978-1-61779-974-7_30.PMID: 22907372

 

Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.

Mohseni Nodehi S, Repp R, Kellner C, Bräutigam J, Staudinger M, Schub N, Peipp M, Gramatzki M, Humpe A.PLoS One. 2012;7(8):e42426. doi: 10.1371/journal.pone.0042426. Epub 2012 Aug 3.PMID: 22879978 Free PMC article.

 

2011

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.PMID: 21855548

 

 

 

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).

Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T.Cancer Sci. 2011 Oct;102(10):1761-8. doi: 10.1111/j.1349-7006.2011.02019.x. Epub 2011 Aug 4.PMID: 21718386 Free article.

 

Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.

Kellner C, Bleeker WK, Lammerts van Bueren JJ, Staudinger M, Klausz K, Derer S, Glorius P, Muskulus A, de Goeij BE, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.J Immunol Methods. 2011 Aug 31;371(1-2):122-33. doi: 10.1016/j.jim.2011.06.023. Epub 2011 Jun 30.PMID: 21756911

 

Molecular engineering to improve antibodies' anti-lymphoma activity.

Peipp M, van de Winkel JG, Valerius T.Best Pract Res Clin Haematol. 2011 Jun;24(2):217-29. doi: 10.1016/j.beha.2011.03.004. Epub 2011 May 7.PMID: 21658620 Review.

 

Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells.

Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, Barbin K, Stein C, Peipp M, Stockmeyer B, Fey GH.Cancer Lett. 2011 Apr 28;303(2):128-39. doi: 10.1016/j.canlet.2011.01.020. Epub 2011 Feb 19.PMID: 21339041

 

Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.

Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, van de Winkel JG, Dechant M, Valerius T.J Immunol. 2011 Mar 15;186(6):3770-8. doi: 10.4049/jimmunol.1003082. Epub 2011 Feb 11.PMID: 21317397

 

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW.J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27.PMID: 21187443 Clinical Trial.

2010

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.

Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, Richards JO, Chen H, Repp R, Desjarlais JR, Zhukovsky EA.Blood. 2010 Oct 21;116(16):3004-12. doi: 10.1182/blood-2010-01-265280. Epub 2010 Jul 8.PMID: 20616215 Free article.

 

Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.

Lohse S, Peipp M, Beyer T, Valerius T, Dechant M.Arch Immunol Ther Exp (Warsz). 2010 Aug;58(4):303-12. doi: 10.1007/s00005-010-0081-2. Epub 2010 May 28.PMID: 20508996

 

Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.

Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M, Lazar GA, Schneider-Merck T, Peipp M, Valerius T.Cancer Sci. 2010 May;101(5):1080-8. doi: 10.1111/j.1349-7006.2010.01505.x. Epub 2010 Jan 20.PMID: 20331636 Free article.

2009

A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.

Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M, Horner H, Thierschmidt D, Valerius T, Repp R, Fey GH, Stockmeyer B.J Immunol. 2010 Feb 1;184(3):1210-7. doi: 10.4049/jimmunol.0902033. Epub 2009 Dec 30.PMID: 20042573

 

Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.

Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, Parren PW, van de Winkel JG, Valerius T, Dechant M.J Immunol. 2010 Jan 1;184(1):512-20. doi: 10.4049/jimmunol.0900847. Epub 2009 Nov 30.PMID: 19949082

 

Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.

Peipp M, Dechant M, Valerius T.MAbs. 2009 Nov-Dec;1(6):590-9. doi: 10.4161/mabs.1.6.10051. Epub 2009 Nov 11.PMID: 20068398 Free PMC article. Review. 

Serum-free production and purification of chimeric IgA antibodies.

Beyer T, Lohse S, Berger S, Peipp M, Valerius T, Dechant M.J Immunol Methods. 2009 Jul 31;346(1-2):26-37. doi: 10.1016/j.jim.2009.05.002. Epub 2009 May 7.PMID: 19427867

2008

A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.

Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH.J Immunother. 2008 Nov-Dec;31(9):871-84. doi: 10.1097/CJI.0b013e318186c8b4.PMID: 18833000

 

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.Cancer Res. 2008 Oct 1;68(19):8049-57. doi: 10.1158/0008-5472.CAN-08-2268.PMID: 18829563

 

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, Parren PW, Valerius T.Blood. 2008 Sep 15;112(6):2390-9. doi: 10.1182/blood-2008-03-144600. Epub 2008 Jun 19.PMID: 18566325 Free article.

 

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.

Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, Yang YG, Jeong JH, Lee KY, Kim YH, Kim SW, Peipp M, Fey GH, Manjunath N, Shultz LD, Lee SK, Shankar P.Cell. 2008 Aug 22;134(4):577-86. doi: 10.1016/j.cell.2008.06.034. Epub 2008 Aug 7.PMID: 18691745 Free PMC article.

 

Effector mechanisms of therapeutic antibodies against ErbB receptors.

Peipp M, Dechant M, Valerius T.Curr Opin Immunol. 2008 Aug;20(4):436-43. doi: 10.1016/j.coi.2008.05.012. Epub 2008 Jul 1.PMID: 18585454 Review.

Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.

Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, Valerius T.Cancer Res. 2008 Jul 1;68(13):4998-5003. doi: 10.1158/0008-5472.CAN-07-6226.PMID: 18593896 Free article.

 

The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.

Lammerts van Bueren JJ, Bleeker WK, Brännström A, von Euler A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW.Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6109-14. doi: 10.1073/pnas.0709477105. Epub 2008 Apr 21.PMID: 18427122 Free PMC article. Retracted.

 

A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.

Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kügler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dörrie J, Ferrone S, Kämpgen E, Fey GH.Melanoma Res. 2008 Apr;18(2):73-84. doi: 10.1097/CMR.0b013e3282f7c8f9.PMID: 18337643 Free PMC article.

 

Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations.

Peipp M, Schneider-Merck T, Dechant M, Beyer T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, Valerius T.J Immunol. 2008 Mar 15;180(6):4338-45. doi: 10.4049/jimmunol.180.6.4338.PMID: 18322248

 

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.

Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Bühring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W.Cancer Immunol Immunother. 2008 Feb;57(2):233-46. doi: 10.1007/s00262-007-0370-8. Epub 2007 Jul 31.PMID: 17665197

2007

Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor.

Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JG, Valerius T.J Immunol. 2007 Sep 1;179(5):2936-43. doi: 10.4049/jimmunol.179.5.2936.PMID: 17709508

 

A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.

Schwemmlein M, Stieglmaier J, Kellner C, Peipp M, Saul D, Oduncu F, Emmerich B, Stockmeyer B, Lang P, Beck JD, Fey GH.Leukemia. 2007 Jul;21(7):1405-12. doi: 10.1038/sj.leu.2404687. Epub 2007 May 10.PMID: 17495978

 

Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway.

Wruck CJ, Claussen M, Fuhrmann G, Römer L, Schulz A, Pufe T, Waetzig V, Peipp M, Herdegen T, Götz ME.J Neural Transm Suppl. 2007;(72):57-67. doi: 10.1007/978-3-211-73574-9_9.PMID: 17982879

2006

A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.

Schwemmlein M, Peipp M, Barbin K, Saul D, Stockmeyer B, Repp R, Birkmann J, Oduncu F, Emmerich B, Fey GH.Br J Haematol. 2006 Apr;133(2):141-51. doi: 10.1111/j.1365-2141.2005.05869.x.PMID: 16611304 Free article.

2005

Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).

Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R, Valerius T, Fey GH.Br J Haematol. 2005 Jul;130(2):218-28. doi: 10.1111/j.1365-2141.2005.05414.x.PMID: 16029450 Free article.

Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.

Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, Gramatzki M, de Leij LF, Helfrich W.Cancer Res. 2005 Apr 15;65(8):3380-8. doi: 10.1158/0008-5472.CAN-04-2756.PMID: 15833872

2004

Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor.

Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, Gramberg T, Pöhlmann S.Biochem Biophys Res Commun. 2004 Jul 9;319(4):1216-21. doi: 10.1016/j.bbrc.2004.05.114.PMID: 15194496 Free PMC article.

 

Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts.

Lang P, Barbin K, Feuchtinger T, Greil J, Peipp M, Zunino SJ, Pfeiffer M, Handgretinger R, Niethammer D, Fey GH.Blood. 2004 May 15;103(10):3982-5. doi: 10.1182/blood-2003-05-1735. Epub 2004 Feb 5.PMID: 14764538 Free article.

 

A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.

Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, Titgemeyer F, Niederweis M, Peipp M, Zunino SJ, Repp R, Valerius T, Fey GH.Br J Haematol. 2004 Apr;125(2):167-79. doi: 10.1111/j.1365-2141.2004.04893.x.PMID: 15059139 Free article.

 

Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications.

Peipp M, Saul D, Barbin K, Bruenke J, Zunino SJ, Niederweis M, Fey GH.J Immunol Methods. 2004 Feb 15;285(2):265-80. doi: 10.1016/j.jim.2003.12.001.PMID: 14980440

2002

Bispecific antibodies targeting cancer cells.

Peipp M, Valerius T.Biochem Soc Trans. 2002 Aug;30(4):507-11. doi: 10.1042/bst0300507.PMID: 12196124 Review.

 

A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells.

Peipp M, Küpers H, Saul D, Schlierf B, Greil J, Zunino SJ, Gramatzki M, Fey GH.Cancer Res. 2002 May 15;62(10):2848-55.PMID: 12019163

2001

An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells.

Peipp M, Simon N, Loichinger A, Baum W, Mahr K, Zunino SJ, Fey GH.J Immunol Methods. 2001 May 1;251(1-2):161-76. doi: 10.1016/s0022-1759(01)00298-8.PMID: 11292491 Free PMC article.